


CLAIMS

1. A compound of the general formula (I):

5



wherein A is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- 10 • C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - o R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - o R₄ represents aryl optionally substituted with one or more halogens; or

15 A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- 20 • C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - o R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - o R₄ represents aryl optionally substituted with one or more halogens; and

25

30 B is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or

90

- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
 - NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - R₄ represents aryl optionally substituted with one or more halogens; or
- 10 B is -O-B' or -S-B' wherein -O- or -S- is linked to Y in formula (I) and wherein B' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from
 - halogen or
 - C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio or aralkoxy each of which is optionally substituted with one or more halogens; or
 - NR₁R₂ wherein R₁ represents hydrogen or C₁₋₃-alkyl and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or arylene optionally substituted with one or more halogens;
 - R₄ represents aryl optionally substituted with one or more halogens; and

D is H, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; and

E is H, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; and

- 25 L and M are independently -O- or -S-; and

T is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from

- 30
 - halogen or hydroxy; or
 - aryl, aralkoxy or C₁₋₃-alkoxy which is optionally substituted with halogen; or

T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl;

- 35 and

U is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from

- halogen or hydroxy; or
- 5 • aryl, aralkoxy or C₁₋₃-alkoxy which is optionally substituted with halogen; or

U is –NR₁-U' wherein –NR₁- is linked to Z in formula (I) and wherein U' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl; and

- 10 X is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from
- halogen or hydroxy; or

- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio, aryl, aralkyl each of which is optionally substituted with one or more halogens; or

Y is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from

- 20 • halogen or hydroxy; or
- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio aryl, aralkyl each of which is optionally substituted with one or more halogens; or

- 25 Z is arylene, heteroarylene or a divalent polycyclic ringsystem each of which is optionally substituted with one or more substituents selected from

- halogen, oxo or hydroxy; or
- C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkylthio each of which is optionally substituted with one or more halogen; or

- 30 a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or any tautomeric forms, stereoisomers, mixture of stereoisomers, racemic mixture, or polymorphs.

2. A compound according to claim 1 wherein A is C₁₋₃-alkylene, which is optionally substituted with one or more substituents selected from

- methyl, C₁₋₃-alkoxy, C₃₋₆-cycloalkoxy or benzyloxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or phenylene optionally substituted with one or more halogens;
 - R₄ represents phenyl optionally substituted with one or more halogens.

10

3. A compound according to claim 2 wherein A is methylene or ethylene each of which is optionally substituted with one or more substituents selected from

- methoxy or ethoxy; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein R₃ and R₄ represents phenyl.

4. A compound according to claim 2 wherein A is ethylene which is optionally substituted with ethoxy.

20

5. A compound according to claim 1 wherein A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy or aralkoxy each of which is optionally substituted with halogen.

6. A compound according to claim 5 wherein A is -O-A' or -S-A' wherein -O- or -S- is linked to X in formula (I) and wherein A' is methylene or ethylene each of which is optionally substituted with one or more substituents selected from methyl, methoxy or ethoxy.

30

7. A compound according to claim 6 wherein A is -O-A' wherein -O- is linked to X in formula (I) and wherein A' is methylene or ethylene.

8. A compound according to claim 7 wherein A is -O-A' wherein -O- is linked to X in formula

35 (I) and wherein A' is methylene.

9. A compound according to claim 1 wherein B is C₁₋₃-alkylene, which is optionally substituted with one or more substituents selected from

- methyl, C₁₋₃-alkoxy, C₃₋₆-cycloalkoxy or benzyloxy each of which is optionally substituted with one or more halogens; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein:
 - R₃ represents C₁₋₆-alkylene, C₂₋₆-alkenylene, C₄₋₆-cycloalkylene, C₄₋₆-cycloalkenylene, or phenylene optionally substituted with one or more halogens;
 - R₄ represents phenyl optionally substituted with one or more halogens.

10

10. A compound according to claim 9 wherein B is methylene or ethylene each of which is optionally substituted with one or more substituents selected from

15

- methoxy or ethoxy; or
- NR₁R₂ wherein R₁ represents hydrogen and R₂ represents -R₃-(C=O)-R₄ wherein R₃ and R₄ represents phenyl.

11. A compound according to claim 9 wherein B is ethylene which is optionally substituted with ethoxy.

20

12. A compound according to claim 1 wherein B is -O-B' or -S-B' wherein -O- or -S- is linked to Y in formula (I) and wherein B' is C₁₋₃-alkylene which is optionally substituted with one or more substituents selected from

25

- halogen or
- C₁₋₃-alkyl, C₁₋₆-alkoxy, C₃₋₆-cycloalkoxy or aralkoxy each of which is optionally substituted with halogen.

30

13. A compound according to claim 12 wherein B is -O-B' or -S-B' wherein -O- or -S- is linked to Y in formula (I) and wherein B' is methylene or ethylene each of which is optionally substituted with one or more substituents selected from methyl, methoxy or ethoxy.

14. A compound according to claim 13 wherein B is -O-B' wherein -O- is linked to Y in formula (I) and wherein B' is methylene or ethylene.

15. A compound according to claim 14 wherein B is -O-B' wherein -O- is linked to Y in formula (I) and wherein B' is methylene.

16. A compound according to claim 1 wherein D is H.

5

17. A compound according to claim 1 wherein D is methyl or ethyl.

18. A compound according to claim 1 wherein D is isopropyl.

10 19. A compound according to claim 1 wherein E is H.

20. A compound according to claim 1 wherein E is methyl or ethyl.

21. A compound according to claim 1 wherein E is isopropyl.

15

22. A compound according to claim 1 wherein L is -O-.

23. A compound according to claim 1 wherein L is -S-.

20 24. A compound according to claim 1 wherein M is -O-.

25. A compound according to claim 1 wherein M is -S-.

26. A compound according to claim 1 wherein T is C₁₋₆ divalent saturated carbon chain optionally substituted with one or more substituents selected from phenyl, benzyloxy or C₁₋₃-alkoxy which is optionally substituted with halogen.

27. A compound according to claim 26 wherein T is an unsubstituted C₁₋₆ divalent saturated carbon chain.

30

28. A compound according to claim 27 wherein T is ethylene or propylene.

29. A compound according to claim 1 wherein T is -NR₁-T' wherein -NR₁- is linked to Z in formula (I) and wherein T' is C₁₋₆ alkylene which is optionally substituted with one or more halogen and R₁ represents hydrogen or C₁₋₃ alkyl.

30. A compound according to claim 29 wherein T is $-NR_1-T'$ wherein $-NR_1-$ is linked to Z in formula (I) and wherein T' is C_{1-3} alkylene and R_1 represents hydrogen or C_{1-3} alkyl.
- 5 31. A compound according to claim 30 wherein T is $-NR_1-T'$ wherein $-NR_1-$ is linked to Z in formula (I) and wherein T' is ethylene and R_1 is methyl.
- 10 32. A compound according to claim 1 wherein U is C_{1-6} divalent saturated carbon chain optionally substituted with one or more substituents selected from phenyl, benzyloxy or C_{1-3} -alkoxy which is optionally substituted with halogen.
- 15 33. A compound according to claim 32 wherein U is an unsubstituted C_{1-6} divalent saturated carbon chain.
- 20 34. A compound according to claim 33 wherein U is ethylene or propylene.
- 25 35. A compound according to claim 1 wherein U is $-NR_1-U'$ wherein $-NR_1-$ is linked to Z in formula (I) and wherein U' is C_{1-6} alkylene which is optionally substituted with one or more halogen and R_1 represents hydrogen or C_{1-3} alkyl.
- 30 36. A compound according to claim 35 wherein U is $-NR_1-U'$ wherein $-NR_1-$ is linked to Z in formula (I) and wherein U' is C_{1-3} alkylene and R_1 represents hydrogen or C_{1-3} alkyl.
- 35 37. A compound according to claim 36 wherein U is $-NR_1-U'$ wherein $-NR_1-$ is linked to Z in formula (I) and wherein U' is ethylene and R_1 is methyl.
- 40 38. A compound according to claim 1 wherein X is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from
- 45 • halogen; or
- 50 • C_{1-6} -alkyl, C_{1-6} -alkoxy, aryl each of which is optionally substituted with one or more halogen.
- 55 39. A compound according to claim 38 wherein X is arylene optionally substituted with one or more substituents selected from
- 60 • halogen; or

- C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
40. A compound according to claim 39 wherein X is phenylene optionally substituted with
5 one or more substituents selected from
 - halogen; or
 - C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl each of which is optionally substituted with one or more halogen.
- 10 41. A compound according to claim 40 wherein X is phenylene optionally substituted with one or more halogen, methyl or phenyl.
42. A compound according to claim 40 wherein X is phenylene optionally substituted with one or more trifluoromethyl or methoxy.
- 15 43. A compound according to claim 1 wherein Y is arylene or heteroarylene each of which is optionally substituted with one or more substituents selected from
 - halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
- 20 44. A compound according to claim 43 wherein Y is arylene optionally substituted with one or more substituents selected from
 - halogen; or
 - C₁₋₆-alkyl, C₁₋₆-alkoxy, aryl each of which is optionally substituted with one or more halogen.
- 25 45. A compound according to claim 44 wherein Y is phenylene optionally substituted with one or more substituents selected from
 - halogen; or
 - C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl each of which is optionally substituted with one or more halogen.
- 30 46. A compound according to claim 45 wherein Y is phenylene optionally substituted with one or more halogen, methyl or phenyl.


47. A compound according to claim 45 wherein Y is phenylene optionally substituted with one or more trifluoromethyl or methoxy.

5 48. A compound according to claim 1 wherein Z is arylene, heteroarylene or a divalent polycyclic ringsystem each of which is optionally substituted with one or more substituents selected from

- halogen, oxo; or
- C₁₋₆-alkyl, C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.

10


49. A compound according to claims 48 wherein Z is selected among the following groups:



15 each of which is optionally substituted with one or more substituents selected from

- halogen; or
- C₁₋₆-alkyl or C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.


20 50. A compound according to claim 49 wherein Z is selected among the following groups:



each of which is optionally substituted with one or more substituents selected from

- halogen; or
- 5 • C₁₋₆-alkyl or C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.


51. A compound according to claim 50 wherein Z is selected among the following groups:



10 each of which is optionally substituted with one or more substituents selected from

- halogen; or
- C₁₋₆-alkyl or C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.

15 52. A compound according to claim 51 wherein Z is selected among the following groups:



each of which is optionally substituted with one or more substituents selected from

- halogen; or


- C₁₋₆-alkyl or C₁₋₆-alkoxy each of which is optionally substituted with one or more halogen.

53. A compound according to claim 52 wherein Z is:



5


54. A compound according to claim 52 wherein Z is:




which is optionally substituted with one or more trifluoromethyl.

10

55. A compound according to claim 52 wherein Z is:




56. A compound according to claim 51 wherein Z is:



15

57. A compound according to claim 51 wherein Z is:



20

58. The compound according to claim 1 which is selected from the following group:

2-Ethoxy-3-[4-(2-{[6-(2-[4-(2-ethoxy-2-methoxycarbonyl-ethyl)-phenylsulfanyl]-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethylsulfanyl)-phenyl]-propionic acid;

3-[4-(2-{[6-(2-[4-(2-Carboxy-2-ethoxy-ethyl)-2-chloro-phenylsulfanyl]-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethylsulfanyl)-3-chloro-phenyl]-2-ethoxy-propionic acid;

25

(5'-{2-[(6-{[2-(2'-Ethoxycarbonylmethoxy-[1,1';3',1"]terphenyl-5'-yloxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-[1,1';3',1"]terphenyl-2'-yloxy)-acetic acid;

100

(5'-{2-[{6-[{2-(2'-Carboxymethoxy-[1,1';3',1"]terphenyl-5'-yloxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-{1,1';3',1"]terphenyl-2'-yloxy)-acetic acid;

(S,S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-({6-[{2-{4-[2-(2-benzoyl-phenylamino)-2-methoxy-carbonyl-ethyl]-phenoxy}-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino)-ethoxy]-phenyl}-propionic acid;

(S,S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-({6-[{2-{4-[2-(2-benzoyl-phenylamino)-2-carboxy-ethyl]-phenoxy}-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino)-ethoxy]-phenyl}-propionic acid;

(3-Chloro-4-{2-[{6-[{2-(2-chloro-4-ethoxycarbonylmethyl-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-phenyl)-acetic acid;

(4-{2-[{6-[{2-(4-Carboxymethyl-2-chloro-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-3-chloro-phenyl)-acetic acid;

(3-{2-[{6-[{2-(3-Ethoxycarbonylmethyl-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-phenyl)-acetic acid;

(3-{2-[{6-[{2-(3-Carboxymethyl-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl]-methyl-amino]-ethoxy}-phenyl)-acetic acid;

(S,S)-2-Ethoxy-3-[4-(2-{[6-({2-[4-(2-ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino)-ethoxy]-phenyl]-propionic acid;

(S,S)-3-[4-(2-{[6-({2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl]-methyl-amino)-pyridin-2-yl]-methyl-amino)-ethoxy)-phenyl]-2-ethoxy-propionic acid;

(S,S)-2-Ethoxy-3-{4-[3-(4'-{3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid;

(S,S)-3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

(S,S)-2-Ethoxy-3-{4-[3-(4'-{3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid;

(S,S)-3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

(S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

(S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

(S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

- (S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
- (S,S)-3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-9*H*-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid isopropyl ester;
- 5 (S,S)-3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-9*H*-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;
- (S,S)-2-Ethoxy-3-{4-[3-(7-{3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-9*H*-fluoren-2-yl)-propoxy]-phenyl}-propionic acid isopropyl ester;
- (S,S)-3-{4-[3-(7-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-9*H*-fluoren-2-yl)-propoxy]-10 phenyl}-2-ethoxy-propionic acid;
- [4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- [4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- 15 [4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- [4-(3-{7-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-9*H*-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- [4-(3-{7-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-9*H*-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- 20 (4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- (4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethylsulfanyl)-2-methyl-phenoxy]-acetic acid;
- 25 (S,S)-2-Ethoxy-3-[4-(2-{2-[4'-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid;
- (S,S)-3-[4-(2-{2-[4'-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid;
- (S,S)-2-Ethoxy-3-[4-(2-{2-[3-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid; and
- 30 (S,S)-3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid; or
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

59. The compound according to claim 1 which is selected from the following group:

2-Ethoxy-3-[4-(2-{[6-({2-[4-(2-ethoxy-2-methoxycarbonyl-ethyl)-phenylsulfanyl]-ethyl}-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethylsulfanyl)-phenyl]-propionic acid methyl ester;

(5'-{2-[{6-({2-[2'-Ethoxycarbonylmethoxy-[1,1';3',1"]terphenyl-5'-yloxy)-ethyl]-methyl-amino}-

5 pyridin-2-yl)-methyl-amino]-ethoxy}-[1,1';3',1"]terphenyl-2'-yloxy)-acetic acid ethyl ester;

(S,S)- 2-(2-Benzoyl-phenylamino)-3-{4-[2-{[6-({2-[4-(2-benzoyl-phenylamino)-2-methoxy-carbonyl-ethyl]-phenoxy}-ethyl)-methyl-amino]-pyridin-2-yl]-methyl-amino}-ethoxy]-phenyl}-propionic acid methyl ester;

(3-Chloro-4-{2-[{6-({2-(2-chloro-4-ethoxycarbonylmethyl-phenoxy)-ethyl]-methyl-amino}-

10 pyridin-2-yl)-methyl-amino]-ethoxy}-phenyl)-acetic acid ethyl ester;

(3-{2-[{6-({2-(3-Ethoxycarbonylmethyl-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy}-phenyl)-acetic acid ethyl ester;

(S,S)-2-Ethoxy-3-[4-(2-{[6-({2-[4-(2-ethoxy-2-ethoxycarbonyl-ethyl)-phenoxy]-ethyl}-methyl-amino)-pyridin-2-yl]-methyl-amino}-ethoxy)-phenyl]-propionic acid ethyl ester;

15 (S,S)-2-Ethoxy-3-{4-[3-(4'-{3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid isopropyl ester;

(S,S)-2-Ethoxy-3-{4-[3-(4'-{3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-propionic acid isopropyl ester;

(S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-

20 propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl)-2-ethoxy-propionic acid isopropyl ester;

(S,S)-3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid isopropyl ester;

25 [4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid methyl ester;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

30 [4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid methyl ester;

[4-(3-{7-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-9H-fluoren-2-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid methyl ester;

(4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

35 methyl ester;

(S,S)-2-Ethoxy-3-[4-(2-{2-[4-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid isopropyl ester; and

5 (S,S)-2-Ethoxy-3-[4-(2-{2-[3-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-propionic acid isopropyl ester; or

a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

10 60. The compound according to claim 1 which is selected from the following group:

[4-(3-{4'-[3-(4-Carboxymethylsulfanyl-3-chloro-phenylsulfanyl)-propyl]-3,3'-bis-rifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-chloro-phenylsulfanyl]-acetic acid;

[4-[3-{4'-[3-(4-Carboxymethoxy-3-trifluoromethylphenylsulfanyl)propyl]biphenyl-4-yl]-propyl-sulfanyl]-2-trifluoromethylphenoxy]acetic acid;

15 [4-[3-[4'-[3-(4-Carboxymethoxy-3-chlorophenylsulfanyl)propyl]-3,3'-bis-trifluoromethylbi-phenyl-4-yl]propylsulfanyl]-2-chlorophenoxy]acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-chloro-phenylsulfanyl)-propyl]-biphenyl-4-yl}-propyl-sulfanyl)-2-chloro-phenoxy]acetic acid; and

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methoxy-phenylsulfanyl)-propyl]-biphenyl-4-yl}-propyl-sulfanyl)-2-methoxy-phenoxy]-acetic acid; or

20 a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

61. The compound according to claim 1 which is selected from the following group:

25 3-[4-(2-{[6-(2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl)-methyl-amino]-pyridin-2-yl}-methyl-amino}-ethoxy)-phenyl]-2-ethoxy-propionic acid;

(3-{2-[(6-{[2-(3-Carboxymethyl-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy}-phenyl)-acetic acid;

2-(2-Benzoyl-phenylamino)-3-{4-[2-((6-{(2-{4-[2-(2-benzoyl-phenylamino)-2-carboxy-ethyl]-phenoxy}-ethyl)-methyl-amino]-pyridin-2-yl)-methyl-amino}-ethoxy]-phenyl}-propionic acid;

30 (5'-{2-[(6-{[2-(2'-Carboxymethoxy-[1,1';3',1"]terphenyl-5'-yloxy)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy}-[1,1';3',1"]terphenyl-2'-yloxy)-acetic acid;

3-[4-(2-{[6-(2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-ethyl)-methyl-amino]-pyridin-2-yl}-methyl-amino}-ethylsulfanyl)-phenyl]-2-ethoxy-propionic acid;

- (4-{2-[(6-{[2-(4-Carboxymethyl-2-chloro-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy}-3-chloro-phenyl)-acetic acid;
- (4-{2-[(6-{[2-(4-Carboxymethyl-2-bromo-phenoxy)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy}-3-bromo-phenyl)-acetic acid;
- 5 (4-{2-[(6-{[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;
- (4-{2-[(6-{[2-(4-Carboxymethoxy-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid;
- (3-{2-[(6-{[2-(3-Carboxymethyl-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-phenyl)-acetic acid;
- 10 (4-{2-[(6-{[2-(4-Carboxymethyl-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-phenyl)-acetic acid;
- (4-{2-[(6-{[2-(4-Carboxymethyl-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-phenyl)-acetic acid;
- 15 2-(2-Benzoyl-phenylamino)-3-{4-[2-({6-[{2-(4-[2-(2-benzoyl-phenylamino)-2-carboxy-ethyl]-phenylsulfanyl}-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl}-propionic acid;
- 3-{4-[2-({6-[{2-(4-[2-Carboxy-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-ethyl]-phenylsulfanyl}-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl]-phenyl}-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid;
- 20 3-{4-[2-({6-[{2-(4-[2-Carboxy-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-ethyl]-phenoxy}-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethoxy]-phenyl}-2-(1-methyl-3-oxo-3-phenyl-propenylamino)-propionic acid;
- (4-{2-[(6-{[2-(4-Carboxymethyl-2-chloro-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-3-chloro-phenyl)-acetic acid;
- 25 (4-{2-[(6-{[2-(4-Carboxymethyl-2-bromo-phenylsulfanyl)-ethyl]-methyl-amino}-pyridin-2-yl)-methyl-amino]-ethylsulfanyl}-3-bromo-phenyl)-acetic acid;
- 3-[4-(2-{3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl)-ethoxy]-phenyl]-2-ethoxy-propionic acid;
- (4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl})-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;
- 30 (4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenoxy)-ethyl]-5-methyl-oxazol-2-yl})-phenyl]-5-methyl-oxazol-4-yl]-ethoxy)-2-methyl-phenoxy)-acetic acid;
- (4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenoxy)-ethyl]-5-methyl-oxazol-2-yl})-phenyl]-5-methyl-oxazol-4-yl]-ethoxy)-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-phenoxy)-acetic acid;

3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-ethyl}-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl}-ethylsulfanyl)-phenyl]-2-ethoxy-propionic acid;

5

3-{4-[3-(7-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

3-{4-[3-(7-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-propyl}-9H-fluoren-2-yl)-propylsulfanyl]-phenyl}-2-ethoxy-propionic acid;

10 [4-(3-{7-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl}-9H-fluoren-2-yl)-propylsulfanyl]-2-methyl-phenoxy)-acetic acid;

[4-(3-{7-[3-(4-Carboxymethoxy-phenylsulfanyl)-propyl}-9H-fluoren-2-yl)-propylsulfanyl]-phenoxy)-acetic acid;

3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-9H-fluoren-2-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

15 3-{3-Bromo-4-[3-(7-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenylsulfanyl]-propyl}-9H-fluoren-2-yl)-propylsulfanyl]-phenyl}-2-ethoxy-propionic acid;

3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-

20 biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

25 3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy)-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-phenylsulfanyl)-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-

30 propylsulfanyl)-phenoxy)-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-phenoxy)-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy)-phenoxy)-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl}-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy)-2-methyl-phenoxy)-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propoxy)-2-methyl-phenoxy]-acetic acid; and

- 5 3-[4-(2-{2-[4'-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl}-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid; or
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

- 10 62. A compound which is {4-[3-(4-{3-(4-Carboxymethoxy-3-trifluoromethyl-phenyl-sulfanyl)-propyl]-2-trifluoromethyl-phenylsulfanyl}-3-trifluoromethyl-phenyl)-propylsulfanyl]-2-trifluoromethyl-phenoxy}-acetic acid or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

15

63. A compound according to claim 1, which is a PPAR δ agonist.

64. A compound according to claim 63, which is a selective PPAR δ agonist.

- 20 65. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

- 25 66. A pharmaceutical composition according to claim 65 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day of compound.

- 30 67. A pharmaceutical composition for the treatment of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising a compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

68. A pharmaceutical composition for the treatment of type I diabetes, type II diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity), cardiovascular diseases

(including atherosclerosis) or hypercholesterolemia comprising a compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

69. A pharmaceutical composition according to claim 65 for oral, nasal, transdermal, pulmonal, 5 or parenteral administration.

70. A method for the treatment of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a 10 pharmaceutical composition comprising the same.

71. A method for the treatment of type I diabetes, type II diabetes, dyslipidemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) or 15 hypercholesterolemia, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or of a pharmaceutical composition comprising the same.

72. The method according to claim 70 wherein the effective amount of the compound is in 20 the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.

73. The method according to claim 71 wherein the effective amount of the compound is in 25 the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 to about 500 mg of and especially preferred from about 0.5 mg to about 200 mg per day.